[go: up one dir, main page]

MX2016007869A - Composiciones de ketoprofeno de accion prolongada. - Google Patents

Composiciones de ketoprofeno de accion prolongada.

Info

Publication number
MX2016007869A
MX2016007869A MX2016007869A MX2016007869A MX2016007869A MX 2016007869 A MX2016007869 A MX 2016007869A MX 2016007869 A MX2016007869 A MX 2016007869A MX 2016007869 A MX2016007869 A MX 2016007869A MX 2016007869 A MX2016007869 A MX 2016007869A
Authority
MX
Mexico
Prior art keywords
long
acting
composition
animal
optionally
Prior art date
Application number
MX2016007869A
Other languages
English (en)
Other versions
MX373714B (es
Inventor
Stephen Lee Secreast
Richard Andrew Ewin
X Hu Steven
M Machkovech Susan
H Manning Barton
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52347413&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016007869(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of MX2016007869A publication Critical patent/MX2016007869A/es
Publication of MX373714B publication Critical patent/MX373714B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención describe una composición veterinaria de acción prolongada que comprende al menos un profármaco de éster de ketoprofeno; la composición también comprende al menos un triglicérido veterinariamente aceptable y, opcionalmente, al menos un conservador y, opcionalmente, al menos un excipiente veterinariamente aceptable adicional; la invención también describe un método de tratamiento de un animal para la fiebre, el dolor y/o la inflamación mediante la administración de la composición de acción prolongada que comprende al menos un profármaco de éster de ketoprofeno al animal que lo necesita.
MX2016007869A 2013-12-16 2014-12-15 Composiciones de ketoprofeno de accion prolongada. MX373714B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361916462P 2013-12-16 2013-12-16
PCT/US2014/070336 WO2015095045A1 (en) 2013-12-16 2014-12-15 Long-acting ketoprofen compositions

Publications (2)

Publication Number Publication Date
MX2016007869A true MX2016007869A (es) 2016-10-07
MX373714B MX373714B (es) 2020-05-08

Family

ID=52347413

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016007869A MX373714B (es) 2013-12-16 2014-12-15 Composiciones de ketoprofeno de accion prolongada.

Country Status (16)

Country Link
US (1) US10632095B2 (es)
EP (1) EP3082762B1 (es)
JP (2) JP6306188B2 (es)
KR (1) KR101817028B1 (es)
CN (2) CN105848638A (es)
AU (1) AU2014366221C1 (es)
CA (1) CA2931858C (es)
CL (1) CL2016001350A1 (es)
DK (1) DK3082762T3 (es)
ES (1) ES2901706T3 (es)
MX (1) MX373714B (es)
NZ (1) NZ719783A (es)
PH (1) PH12016500910A1 (es)
PL (1) PL3082762T3 (es)
RU (1) RU2646829C1 (es)
WO (1) WO2015095045A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105848638A (zh) * 2013-12-16 2016-08-10 硕腾服务有限责任公司 长效酮洛芬组合物
US9714403B2 (en) 2014-06-19 2017-07-25 E I Du Pont De Nemours And Company Compositions containing one or more poly alpha-1,3-glucan ether compounds
CA3085488A1 (en) 2017-12-11 2019-06-20 Meat & Livestock Australia Ltd Transdermal analgesic formulation
JP2021534207A (ja) * 2018-08-24 2021-12-09 セントレクシオン セラピューティクス コーポレイション 膝関節痛の治療のためのカプサイシン連続投薬方法
CN115252625B (zh) * 2022-08-11 2024-01-26 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 一种环维黄杨星d在制备治疗非洲猪瘟的制剂中的应用
KR102798067B1 (ko) * 2023-11-07 2025-04-23 주식회사 삼양애니팜 아목시실린을 포함하는 반려동물용 지속형 항생제 및 이의 용도

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1709232A (en) * 1927-12-19 1929-04-16 James J Richardson Steering mechanism
FR1546478A (fr) 1967-01-27 1968-11-22 Rhone Poulenc Sa Nouveaux dérivés de l'acide benzoyl-3 phénylacétique et leur préparation
US4560785A (en) 1983-03-02 1985-12-24 Ss Pharmaceutical Co., Ltd. Phenylacetic ester derivatives and process for preparing the same
DE3324193A1 (de) 1983-07-05 1985-01-17 Troponwerke Gmbh & Co Kg Depot-antiphlogistika
US6217911B1 (en) * 1995-05-22 2001-04-17 The United States Of America As Represented By The Secretary Of The Army sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres
GB9118149D0 (en) * 1991-08-22 1991-10-09 Enzymatix Ltd Araylalkanoic acid resolution
HRP20000366B1 (en) * 1997-12-03 2009-08-31 Merck & Co. Inc. Long acting injectable formulations containing hydrogenated castor oil
KR20010013712A (ko) * 1998-04-11 2001-02-26 엘레카빠 유로테라삐치 에스.피.에이. 수용성 케토프로펜 염을 함유하는 약학적 제제 및 그의 용도
US7666914B2 (en) * 2004-06-03 2010-02-23 Richlin David M Topical preparation and method for transdermal delivery and localization of therapeutic agents
CN1709232A (zh) * 2005-06-15 2005-12-21 沈阳药科大学 含有酮洛芬或酮洛芬酯的注射用脂质微球及其制备工艺
JP2010508289A (ja) * 2006-10-27 2010-03-18 ノーヴェン ファーマシューティカルズ インコーポレイテッド ケトプロフェン極性誘導体の経皮的送達
MX2011005217A (es) 2008-11-19 2011-06-01 Merial Ltd Formulaciones que comprenden ceftiofur y cetoprofeno o ceftiofur y alcohol bencilico.
FR2950533B1 (fr) 2009-09-28 2012-01-13 Maco Pharma Sa Formulation liquide, stable, prete a l'emploi de ketoprofene
CN102648897A (zh) * 2012-04-28 2012-08-29 东华大学 一种酮洛芬高分子前药聚合物微球及其制备方法
CN105848638A (zh) * 2013-12-16 2016-08-10 硕腾服务有限责任公司 长效酮洛芬组合物

Also Published As

Publication number Publication date
BR112016012235A2 (pt) 2017-08-08
RU2016121639A (ru) 2018-01-23
JP2016539997A (ja) 2016-12-22
PH12016500910A1 (en) 2016-06-20
AU2014366221B2 (en) 2019-06-13
EP3082762A1 (en) 2016-10-26
CL2016001350A1 (es) 2016-11-25
BR112016012235A8 (pt) 2018-01-30
PL3082762T3 (pl) 2022-02-14
EP3082762B1 (en) 2021-11-17
CN105848638A (zh) 2016-08-10
KR20160078491A (ko) 2016-07-04
US10632095B2 (en) 2020-04-28
DK3082762T3 (da) 2021-12-06
WO2015095045A1 (en) 2015-06-25
JP6306188B2 (ja) 2018-04-04
CA2931858C (en) 2018-12-11
AU2014366221C1 (en) 2019-10-03
ES2901706T3 (es) 2022-03-23
US20160303065A1 (en) 2016-10-20
CA2931858A1 (en) 2015-06-25
JP2018058880A (ja) 2018-04-12
MX373714B (es) 2020-05-08
CN112843042A (zh) 2021-05-28
NZ719783A (en) 2017-01-27
KR101817028B1 (ko) 2018-01-09
RU2646829C1 (ru) 2018-03-07
AU2014366221A1 (en) 2016-05-26

Similar Documents

Publication Publication Date Title
ZA202308495B (en) Pharmaceutical compositions of therapeutically active compounds
IL287731A (en) A prolonged-release preparation for administration by injection for the treatment of arthritis and pain as a result
PH12016500910A1 (en) Long-acting ketoprofen compositions
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
PH12016501788A1 (en) Pharmaceutical compositions of therapeutically active compounds
MX375254B (es) Una composición antimicrobiana farmacéutica o veterinaria intramamaria que comprende un poliéter ionóforo, o un uso de la misma para tratar mastitis.
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
MX2015003074A (es) Formulaciones que comprenden idebenona, n-acetil-s-farnesil-l-cist eína y ergotioneína y usos de las mismas.
MX2020001428A (es) Composiciones de grapiprant y metodos para usar las mismas.
DK3003363T3 (da) Immunogen sammensætning til anvendelse i terapi
BR112015016391A2 (pt) carboxamidas i baseadas em pirazolil como inibidoras do canal crac
BR112015016394A2 (pt) carboxamidas ii baseadas em pirazolil como inibidoras do canal crac
MX2014014814A (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
MX388831B (es) Metodos y composiciones para esteres anticolinergicos suaves.
MX366118B (es) Combinacion sinergistica de paracetamol/celecoxib para el tratamiento de dolor inflamatorio.
MX368640B (es) Composición farmacéutica para tratar inflamación y dolor.
IN2013MU03428A (es)
AR130700A2 (es) Composiciones de grapiprant y métodos para su utilización
WO2014170820A3 (en) A pharmaceutical combination for treating tuberculosis
AR099681A1 (es) Composiciones de grapiprant y métodos para su utilización
UA91070U (uk) Спосіб профілактики та корекції запальних захворювань на донозологічному рівні
ZA201606135B (en) Pharmaceutical compositions of therapeutically active compounds
PH12014000105A1 (en) Therapeutic methods and compositions for treating diabetes utilizing diterpenoid compounds
MX2016010919A (es) 4-bencilsulfonil-2-butenonitrilo.
IN2014DE00822A (es)

Legal Events

Date Code Title Description
FG Grant or registration